Rhumbline Advisers Uro Gen Pharma Ltd. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 49,868 shares of URGN stock, worth $642,299. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,868
Previous 50,477
1.21%
Holding current value
$642,299
Previous $847,000
25.27%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$48.8 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$48.1 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$29.7 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$28.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$28.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $293M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...